Robert Pyke - Academia.edu (original) (raw)
Papers by Robert Pyke
hysterectomy following surgery (8.9% vs. 5.5%) as those who underwent repeat abdominal myomectomy... more hysterectomy following surgery (8.9% vs. 5.5%) as those who underwent repeat abdominal myomectomy. The interval from first myomectomy to repeat procedure was 4.4 years. CONCLUSION: The hysterectomy rate following primary and repeat myomectomies is low in our cohort. However, repeat procedures are associated with a reduced live birth rate when compared to primary myomectomies. This information may be helpful in counseling patients considering a repeat myomectomy for uterine preservation.
L'invention concerne l'utilisation de flibanserine pour la preparation d'un medicamen... more L'invention concerne l'utilisation de flibanserine pour la preparation d'un medicament destine a traiter les troubles de la libido post-menopausiques.
Sexual medicine reviews, 2018
... and Gynaecology, University of British Columbia, 2775 Laurel Street, 6th Floor, Vancouver, BC... more ... and Gynaecology, University of British Columbia, 2775 Laurel Street, 6th Floor, Vancouver, BC V5Z 1M9, Canada e-mail: lori.brotto@vch.ca ... Our clinical experience, as well as studies of clinical samples (Bancroft, Graham, & McCord, 2001; Basson et al., 2000), suggests that ...
L'invention porte sur de nouvelles compositions pharmaceutiques utiles dans le traitement et/... more L'invention porte sur de nouvelles compositions pharmaceutiques utiles dans le traitement et/ou la prevention de la depression et sur leurs procedes de preparation. Selon une forme d'execution preferee, l'invention porte sur des combinaisons pharmaceutiques comprenant la flibanserine comme ingredient actif en combinaison avec au moins un ingredient actif additionnel, ces combinaisons pharmaceutiques etant utiles dans le traitement et/ou la prevention de la depression. L'invention porte egalement sur les procedes de preparation de ces combinaisons pharmaceutiques.
Clinical …, 1996
To study the analgesic efficacy of enadoline, a selective agonist of the kappa-opioid receptor, a... more To study the analgesic efficacy of enadoline, a selective agonist of the kappa-opioid receptor, a double-blind, randomized comparison was made of enadoline versus placebo and a combination of acetaminophen-codeine in patients with pain after surgical extraction of impacted molar teeth. An initial study involving a comparison of enadoline, a combination, and placebo failed to show any analgesic effect of enadoline. Therefore, a second study with the same design but using higher doses of enadoline was conducted. Despite continued safety and tolerability even at the higher doses, enadoline could not be shown to be superior to placebo. The acetaminophen-codeine combination was significantly more effective than enadoline or placebo. Enadoline did not show analgesic efficacy in this study. Possible reasons for this lack of efficacy are discussed.
Use of a therapeutically effective amount of flibanserin, optionally in form of pharmacologically... more Use of a therapeutically effective amount of flibanserin, optionally in form of pharmacologically acceptable acid addition salts thereto, for the manufacture of a medicament for the treatment of premenstrual disorders.
The journal of sexual medicine, 2005
INTRODUCTION Hypoactive sexual desire disorder (HSDD) is the most common sexual complaint in wome... more INTRODUCTION Hypoactive sexual desire disorder (HSDD) is the most common sexual complaint in women. Currently there are no validated instruments for specifically assessing HSDD severity, or change in HSDD severity in response to treatment, in premenopausal women. The Sexual Interest and Desire Inventory-Female (SIDI-F) is a clinician-administered instrument that was developed to measure severity and change in response to treatment of HSDD. Seventeen items were included in a preliminary version of the SIDI-F, including 10 items related to desire, and seven items related to possible comorbid factors (e.g., other kinds of sexual dysfunction, general relationship satisfaction, mood, and fatigue). AIM The aim of the study was to use the outcome of item response analyses of blinded data from two randomized, placebo-controlled trials, to assist in the revision of the scale. METHODS A nonparametric item response (IRT) model was used to assess the relation between item functioning and HSDD s...
L'invention concerne l'utilisation de la flibanserine pour preparer un medicament destine... more L'invention concerne l'utilisation de la flibanserine pour preparer un medicament destine a traiter les troubles premenopausiques du desir sexuel.
A. An operation, depression, injuries, or other medical condition Yes No B. Medications, drugs, o... more A. An operation, depression, injuries, or other medical condition Yes No B. Medications, drugs, or alcohol you are currently taking Yes No C. Pregnancy, recent childbirth, menopausal symptoms Yes No D. Other sexual issues you may be having (pain, decreased arousal or orgasm) Yes No E. Your partner’s sexual problems Yes No F. Dissatisfaction with your relationship or partner Yes No G. Stress or fatigue Yes No
Journal of sex & marital therapy, Jan 3, 2017
Sexual medicine reviews, Jan 22, 2018
Regarding hypoactive sexual desire disorder (HSDD) in women, some reviewers judge the effect size... more Regarding hypoactive sexual desire disorder (HSDD) in women, some reviewers judge the effect size small for medications vs placebo, but substantial for cognitive behavior therapy (CBT) or mindfulness meditation training (MMT) vs wait list. However, we lack comparisons of the effect sizes for the active intervention itself, for the control treatment, and for the differential between the two. For efficacy trials of HSDD in women, compare effect sizes for medications (testosterone/testosterone transdermal system, flibanserin, and bremelanotide) and placebo vs effect sizes for psychotherapy and wait-list control. We conducted a literature search for mean changes and SD on main measures of sexual desire and associated distress in trials of medications, CBT, or MMT. Effect size was used as it measures the magnitude of the intervention without confounding by sample size. Cohen d was used to determine effect sizes. For medications, mean (SD) effect size was 1.0 (0.34); for CBT and MMT, 1.0 ...
Journal of Sex & Marital Therapy
Tiefer (2017) criticized our recent analysis of psychological treatment trials for HSDD (Pyke &am... more Tiefer (2017) criticized our recent analysis of psychological treatment trials for HSDD (Pyke & Clayton, 2015) on what she claims to be scientific and "political" grounds. In the same letter, she alleged that we, and, by extension, the U.S. Food and Drug Administration, promoted drugs to the detriment of psychological treatment of female sexual problems. Such accusations require a serious response.
Journal of Sex & Marital Therapy
Sexual medicine reviews, Jan 27, 2017
Flibanserin is a postsynaptic 5-HT-1A agonist and 5-HT-2A antagonist for the treatment of general... more Flibanserin is a postsynaptic 5-HT-1A agonist and 5-HT-2A antagonist for the treatment of generalized acquired hypoactive sexual desire disorder in premenopausal women. To review and evaluate the efficacy and safety of flibanserin. We review and critique the appropriateness of the co-primary and secondary end points used in the flibanserin pivotal trial research program. We review the efficacy and safety parameters of this drug based on the published literature and related sources. Pivotal trial primary and secondary end points and safety profile data from the flibanserin development program. Our review identified instances of poor fit of two primary trial pivotal trial end points with the hypoactive sexual desire disorder construct: satisfying sexual events and electronic daily diary assessments of the most intense level of sexual desire experienced each day. Efficacy findings of the flibanserin pivotal trials program were positive for satisfying sexual events, not positive for ele...
hysterectomy following surgery (8.9% vs. 5.5%) as those who underwent repeat abdominal myomectomy... more hysterectomy following surgery (8.9% vs. 5.5%) as those who underwent repeat abdominal myomectomy. The interval from first myomectomy to repeat procedure was 4.4 years. CONCLUSION: The hysterectomy rate following primary and repeat myomectomies is low in our cohort. However, repeat procedures are associated with a reduced live birth rate when compared to primary myomectomies. This information may be helpful in counseling patients considering a repeat myomectomy for uterine preservation.
L'invention concerne l'utilisation de flibanserine pour la preparation d'un medicamen... more L'invention concerne l'utilisation de flibanserine pour la preparation d'un medicament destine a traiter les troubles de la libido post-menopausiques.
Sexual medicine reviews, 2018
... and Gynaecology, University of British Columbia, 2775 Laurel Street, 6th Floor, Vancouver, BC... more ... and Gynaecology, University of British Columbia, 2775 Laurel Street, 6th Floor, Vancouver, BC V5Z 1M9, Canada e-mail: lori.brotto@vch.ca ... Our clinical experience, as well as studies of clinical samples (Bancroft, Graham, & McCord, 2001; Basson et al., 2000), suggests that ...
L'invention porte sur de nouvelles compositions pharmaceutiques utiles dans le traitement et/... more L'invention porte sur de nouvelles compositions pharmaceutiques utiles dans le traitement et/ou la prevention de la depression et sur leurs procedes de preparation. Selon une forme d'execution preferee, l'invention porte sur des combinaisons pharmaceutiques comprenant la flibanserine comme ingredient actif en combinaison avec au moins un ingredient actif additionnel, ces combinaisons pharmaceutiques etant utiles dans le traitement et/ou la prevention de la depression. L'invention porte egalement sur les procedes de preparation de ces combinaisons pharmaceutiques.
Clinical …, 1996
To study the analgesic efficacy of enadoline, a selective agonist of the kappa-opioid receptor, a... more To study the analgesic efficacy of enadoline, a selective agonist of the kappa-opioid receptor, a double-blind, randomized comparison was made of enadoline versus placebo and a combination of acetaminophen-codeine in patients with pain after surgical extraction of impacted molar teeth. An initial study involving a comparison of enadoline, a combination, and placebo failed to show any analgesic effect of enadoline. Therefore, a second study with the same design but using higher doses of enadoline was conducted. Despite continued safety and tolerability even at the higher doses, enadoline could not be shown to be superior to placebo. The acetaminophen-codeine combination was significantly more effective than enadoline or placebo. Enadoline did not show analgesic efficacy in this study. Possible reasons for this lack of efficacy are discussed.
Use of a therapeutically effective amount of flibanserin, optionally in form of pharmacologically... more Use of a therapeutically effective amount of flibanserin, optionally in form of pharmacologically acceptable acid addition salts thereto, for the manufacture of a medicament for the treatment of premenstrual disorders.
The journal of sexual medicine, 2005
INTRODUCTION Hypoactive sexual desire disorder (HSDD) is the most common sexual complaint in wome... more INTRODUCTION Hypoactive sexual desire disorder (HSDD) is the most common sexual complaint in women. Currently there are no validated instruments for specifically assessing HSDD severity, or change in HSDD severity in response to treatment, in premenopausal women. The Sexual Interest and Desire Inventory-Female (SIDI-F) is a clinician-administered instrument that was developed to measure severity and change in response to treatment of HSDD. Seventeen items were included in a preliminary version of the SIDI-F, including 10 items related to desire, and seven items related to possible comorbid factors (e.g., other kinds of sexual dysfunction, general relationship satisfaction, mood, and fatigue). AIM The aim of the study was to use the outcome of item response analyses of blinded data from two randomized, placebo-controlled trials, to assist in the revision of the scale. METHODS A nonparametric item response (IRT) model was used to assess the relation between item functioning and HSDD s...
L'invention concerne l'utilisation de la flibanserine pour preparer un medicament destine... more L'invention concerne l'utilisation de la flibanserine pour preparer un medicament destine a traiter les troubles premenopausiques du desir sexuel.
A. An operation, depression, injuries, or other medical condition Yes No B. Medications, drugs, o... more A. An operation, depression, injuries, or other medical condition Yes No B. Medications, drugs, or alcohol you are currently taking Yes No C. Pregnancy, recent childbirth, menopausal symptoms Yes No D. Other sexual issues you may be having (pain, decreased arousal or orgasm) Yes No E. Your partner’s sexual problems Yes No F. Dissatisfaction with your relationship or partner Yes No G. Stress or fatigue Yes No
Journal of sex & marital therapy, Jan 3, 2017
Sexual medicine reviews, Jan 22, 2018
Regarding hypoactive sexual desire disorder (HSDD) in women, some reviewers judge the effect size... more Regarding hypoactive sexual desire disorder (HSDD) in women, some reviewers judge the effect size small for medications vs placebo, but substantial for cognitive behavior therapy (CBT) or mindfulness meditation training (MMT) vs wait list. However, we lack comparisons of the effect sizes for the active intervention itself, for the control treatment, and for the differential between the two. For efficacy trials of HSDD in women, compare effect sizes for medications (testosterone/testosterone transdermal system, flibanserin, and bremelanotide) and placebo vs effect sizes for psychotherapy and wait-list control. We conducted a literature search for mean changes and SD on main measures of sexual desire and associated distress in trials of medications, CBT, or MMT. Effect size was used as it measures the magnitude of the intervention without confounding by sample size. Cohen d was used to determine effect sizes. For medications, mean (SD) effect size was 1.0 (0.34); for CBT and MMT, 1.0 ...
Journal of Sex & Marital Therapy
Tiefer (2017) criticized our recent analysis of psychological treatment trials for HSDD (Pyke &am... more Tiefer (2017) criticized our recent analysis of psychological treatment trials for HSDD (Pyke & Clayton, 2015) on what she claims to be scientific and "political" grounds. In the same letter, she alleged that we, and, by extension, the U.S. Food and Drug Administration, promoted drugs to the detriment of psychological treatment of female sexual problems. Such accusations require a serious response.
Journal of Sex & Marital Therapy
Sexual medicine reviews, Jan 27, 2017
Flibanserin is a postsynaptic 5-HT-1A agonist and 5-HT-2A antagonist for the treatment of general... more Flibanserin is a postsynaptic 5-HT-1A agonist and 5-HT-2A antagonist for the treatment of generalized acquired hypoactive sexual desire disorder in premenopausal women. To review and evaluate the efficacy and safety of flibanserin. We review and critique the appropriateness of the co-primary and secondary end points used in the flibanserin pivotal trial research program. We review the efficacy and safety parameters of this drug based on the published literature and related sources. Pivotal trial primary and secondary end points and safety profile data from the flibanserin development program. Our review identified instances of poor fit of two primary trial pivotal trial end points with the hypoactive sexual desire disorder construct: satisfying sexual events and electronic daily diary assessments of the most intense level of sexual desire experienced each day. Efficacy findings of the flibanserin pivotal trials program were positive for satisfying sexual events, not positive for ele...